🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Mexico
Clinical trial register · Mexico

Studies with a Mexican investigative site

Every study on the ClinicalTrials.gov registry that lists a site in Mexico and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 1579 matching records held by the registry are in this view. Synced 26 Sep 2026, 19:45 UTC
1579
Studies in scope
all four open statuses
711
Recruiting now
open to new participants
247
Lead sponsors
across recruiting studies
Top sites
Mexico City 586 Monterrey 370 Guadalajara 342 Chihuahua City 175 Mérida 135
Narrow the register
Recruitment status
Phase
Lead sponsor
National Cancer Institute (NCI)116 AstraZeneca66 Merck Sharp & Dohme LLC63 Hoffmann-La Roche61 Eli Lilly and Company56
Site location
Mexico City586 Monterrey370 Guadalajara342 Chihuahua City175 Mérida135
All 197 locations
Target enrolment
to

Trials in this register

1579 of 1579 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Mexico
Start
Recruiting
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
NCT06008197Heart Failure, Acute Heart Failure
DrugFinerenone
Colorado Prevention Center
Phase 3
5,200
Aguascalientes, Culiacán, Guadalajara, Cuauhtémoc, Mexico City, Morelia, Monterrey, San Nicolás
2024-01-17
Recruiting
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
NCT05773274Metastatic Digestive System Neuroendocrine Tumor G1, Metastatic Digestive System Neuroendocrine Tumor G2, Unresectable Digestive System Neuroendocrine Tumor G1, Unresectable Digestive System Neuroendocrine Tumor G2
DrugsLutathera·Sunitinib·Cabozantinib·Everolimus
National Cancer Institute (NCI)
Phase 2
100
2024-01-12
Active, closed
A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment
NCT06105632Advanced or Metastatic Breast Cancer
DrugsExemestane·Everolimus·Fulvestrant
Pfizer
Phase 2
333
Mexico City, Monterrey, Oaxaca City, Veracruz
2024-01-09
Active, closed
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
NCT06116916Diabetic Macular Edema (DME)
DrugsKHK4951·Aflibercept
Kyowa Kirin Co., Ltd.
Phase 2
150
2024-01-09
Recruiting
Postprandial Metabolome and Metabolic Flexibility
NCT06878781Fasting, Postprandial Hyperglycemia, Lipid Metabolism Disorders, Glucose Metabolism Disorders
Instituto Nacional de Medicina Genomica
Not applicable
300
Mexico City
2024-01-08
Active, closed
A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia
NCT05761171Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From Acute Leukemia of Ambiguous Lineage, Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
DrugsFludarabine Phosphate·Revumenib·Calaspargase Pegol·Hydrocortisone Sodium Succinate
Children's Oncology Group
Phase 2
78
2024-01-08
Active, closed
Integrated Care and Treatment for Severe Infectious Diseases and Substance Use Disorders Among Hospitalized Patients
NCT05688423Injection Site Infection, Substance Use Disorders
Columbia University
Not applicable
480
2024-01-05
By invitation
Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS)
NCT06191315Wheezing, Asthma
DrugDupilumab
Sanofi
Phase 3
90
San Juan del Río, Durango, Veracruz
2024-01-03
Active, closed
PD Catheter Survival: Modified Percutaneous vs Moncrief-Popovich
NCT07465445Chronic Kidney Disease (CKD) Stage 5, Peritoneal Dialysis Access
Hospital Civil de Guadalajara
Not applicable
60
Guadalajara
2024-01-01
Recruiting
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT06136624Prostate Cancer Metastatic
DrugsFludrocortisone acetate·Opevesostat·Hydrocortisone·Abiraterone acetate
Merck Sharp & Dohme LLC
Phase 3
1,310
Guadalajara, Mexico City, Monterrey, Mérida
2023-12-31
Recruiting
BradycArdia paCemaKer With AV Interval Modulation for Blood prEssure treAtmenT
NCT06059638Hypertension, Hypertension, Systolic, Hypertension, Essential
Orchestra BioMed, Inc
Not applicable
316
2023-12-27
Active, closed
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
NCT06141486Multiple Sclerosis
DrugFrexalimab
Sanofi
Phase 3
943
2023-12-27
Recruiting
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
NCT06119581Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
DrugsOlomorasib·Pemetrexed·Cisplatin·Carboplatin
Eli Lilly and Company
Phase 3
1,264
Guadalajara, Juriquilla, León, Mexico City, Monterrey, Oaxaca City, Puebla City, San Pedro Garza García
2023-12-21
Recruiting
Proteinopathies Expression in Skin of Neurodegenerative Disorders
NCT06528964Alzheimer Disease, Frontotemporal Dementia, Parkinson Disease, Atypical Parkinsonism
Universidad Autonoma de San Luis Potosí
Observational
40
San Luis Potosí City
2023-12-20
Recruiting
Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer
NCT05950464Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Low Grade Endometrioid Adenocarcinoma
DrugsZEN003694·Tuvusertib
National Cancer Institute (NCI)
Phase 1
65
2023-12-18
Active, closed
A First-in-Human Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7507062 in Participants With Systemic Lupus Erythematosus
NCT05835986Systemic Lupus Erythematosus
DrugTocilizumab
Hoffmann-La Roche
Phase 1
70
Guadalajara, Mexico City
2023-12-18
By invitation
Reconstruction of the ACL With QT Graft With Bone Plug vs BPTB
NCT06189573Anterior Cruciate Ligament Rupture
Instituto Nacional de Rehabilitacion
Not applicable
80
Mexico City
2023-12-18
Recruiting
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT06136650Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostatic Neoplasms
DrugsFludrocortisone acetate·Opevesostat·Prednisone Acetate·Hydrocortisone
Merck Sharp & Dohme LLC
Phase 3
1,314
Guadalajara, Mexico City, Tlalpan, Monterrey
2023-12-18
Active, closed
REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)
NCT05973773Advanced or Metastatic NSCLS With Exon 20 Insertion Mutation
DrugZipalertinib
Taiho Oncology, Inc.
Phase 3
285
Aguascalientes, Guadalajara, Mexico City, Mirador, Veracruz
2023-12-18
Recruiting
Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
NCT06170788Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
614
Guadalajara, Mexico City, Monterrey, San Luis Potosí City, Oaxaca City, Puebla City
2023-12-15
Recruiting
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
NCT05946213Prostate Adenocarcinoma, Stage III Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
NRG Oncology
Phase 3
1,209
2023-12-14
Recruiting
A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
NCT06136559Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
DrugsNemtabrutinib·Ibrutinib·Acalabrutinib
Merck Sharp & Dohme LLC
Phase 3
1,200
Benito Juárez, Mexico City
2023-12-13
Recruiting
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM)
NCT06128629Transthyretin Amyloidosis (ATTR) With Cardiomyopathy
DrugNexiguran ziclumeran
Intellia Therapeutics
Phase 3
1,200
Mexico City
2023-12-13
Active, closed
Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT05554367Exocrine Pancreas Carcinoma, Malignant Solid Neoplasm, Ovarian Low Grade Serous Adenocarcinoma, Stage IV Ovarian Cancer AJCC v8
DrugsBinimetinib·Palbociclib
National Cancer Institute (NCI)
Phase 2
199
2023-12-13
Active, closed
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473Multiple Sclerosis
DrugsCholestyramine·Activated Charcoal·Teriflunomide·Frexalimab
Sanofi
Phase 3
1,655
Guadalajara, Monterrey, Culiacán, Mérida, Mexico City, Tlalnepantla, Veracruz
2023-12-13
Active, closed
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT06065748Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
DrugsGiredestrant·Ribociclib·Abemaciclib·Palbociclib
Hoffmann-La Roche
Phase 3
1,050
Guadalajara, Mexico City, Monterrey, Oaxaca City, Queréaro
2023-12-11
Active, closed
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
NCT05682443Metastatic Castration-resistant Prostate Cancer
DrugsGotistobart·Pluvicto
OncoC4, Inc.
Phase 1/2
148
2023-12-11
Recruiting
Trial of a Six-Month Regimen of High-Dose Rifampicin, High-Dose Isoniazid, Linezolid, and Pyrazinamide Versus a Standard Nine-Month Regimen for the Treatment of Adults and Adolescents With Tuberculous Meningitis
NCT05383742Tuberculous Meningitis
DrugsPyrazinamide·Isoniazid·Ethambutol·Linezolid
National Institute of Allergy and Infectious Diseases (NIAID)
Phase 2
330
Mexico City
2023-12-07
Active, closed
A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
NCT06077760Non-small Cell Lung Cancer
DrugsIntismeran autogene·Pembrolizumab
Merck Sharp & Dohme LLC
Phase 3
868
Pachuca, Guadalajara, Mexico City, Monterrey, Chihuahua City, Distrito Federal, Oaxaca City
2023-12-06
Active, closed
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
NCT05769153Neovascular Age-related Macular Degeneration (nAMD)
DrugAflibercept
Alcon Research
Phase 1/2
139
2023-12-06
Active, closed
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958Endometrial Cancer
DrugsSacituzumab tirumotecan·Doxorubicin·Nab-paclitaxel·Paclitaxel
Merck Sharp & Dohme LLC
Phase 3
710
Coyoacán, Mexico City, San Pedro Garza García, Oaxaca City
2023-12-06
Recruiting
Study of a Novel Type 3 Oral Poliomyelitis Vaccine in Panama
NCT05654467Poliomyelitis
PATH
Phase 2
1,532
2023-12-05
Recruiting
A Study Evaluating Efruxifermin in Subjects With Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Fibrosis
NCT06215716NASH With Fibrosis, MASH With Fibrosis
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
1,650
Cuauhtémoc
2023-12-01
Active, closed
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)
NCT06113445NonSegmental Vitiligo
DrugPovorcitinib
Incyte Corporation
Phase 3
467
Deleg. Cuauhtemoc, Durango, Monterrey, Morelia, Providencia 5TA Seccion
2023-11-29
Recruiting
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
NCT06103864Breast Cancer
DrugsDatopotamab Deruxtecan·Durvalumab·Nab-paclitaxel·Gemcitabine
AstraZeneca
Phase 3
625
CD Mexico, Guadalajara, Mexico City, México, Tuxtla Gutiérrez
2023-11-23
Recruiting
Two Schemes Response in Multiple Myeloma
NCT06284395Response, Acute Phase, Survivorship
DrugBortezomib
Hospital General de Mexico
Observational
83
Mexico City
2023-11-20
Recruiting
Reverse Trigger Phenotypification and Response to Ventilatory Adjustments
NCT06148467Reverse Trigger, Acute Respiratory Distress Syndrome, Mechanical Ventilation
Hospital Civil de Guadalajara
Observational
130
Guadalajara
2023-11-17
Active, closed
OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer
NCT06016738Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, ER Positive Breast Cancer
DrugsPalazestrant·Exemestane·Anastrozole·Letrozole
Olema Pharmaceuticals, Inc.
Phase 3
510
Guadalajara, Mexico City, Puebla City, San Luis Potosí City, Monterrey, Oaxaca City, Sinaloa
2023-11-16
Recruiting
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
NCT05920356Non-Small Cell Lung Cancer (NSCLC)
DrugsSotorasib·Pembrolizumab
Amgen
Phase 3
750
Guadalajara, Mexico City, Monterrey, Oaxaca City
2023-11-16
Active, closed
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478Chronic Spontaneous Urticaria
DrugsOmalizumab·Remibrutinib
Novartis Pharmaceuticals
Phase 3
470
Guadalajara, Cuauhtémoc, Villahermosa, Mérida
2023-11-15
Recruiting
ACP-204 in Adults With Alzheimer's Disease Psychosis
NCT06159673Alzheimer's Disease Psychosis
DrugACP-204
ACADIA Pharmaceuticals Inc.
Phase 2/3
1,074
Monterrey, Coahuila, Estado de México, Mazatlán, Mexico City, Nuevo León, San Luis Potosí City, Sinaloa
2023-11-14
Active, closed
Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
NCT06074588Non-small Cell Lung Cancer (NSCLC)
DrugsSacituzumab tirumotecan·Pemetrexed·Docetaxel
Merck Sharp & Dohme LLC
Phase 3
556
Guadalajara, Monterrey, Oaxaca City, Puebla City
2023-11-12
Active, closed
A Study Evaluating Efruxifermin in Subjects With Non-invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Nonalcoholic Fatty Liver Disease (NAFLD)/Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
NCT06161571NASH/MASH, NAFLD/MASLD
DrugEfruxifermin
Akero Therapeutics, Inc
Phase 3
700
Mexico City
2023-11-10
Recruiting
Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Versus Darunavir/Cobicistat Plus Tenofovir/Emtricitabine in Virologically Suppressed HIV-1-positive Individuals in Mexico
NCT06907056HIV Infection
DrugDolutegravir/Lamivudine
José Antonio Mata Marín
Phase 4
138
Mexico City
2023-11-09
Active, closed
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183Stable Nonsegmental Vitiligo, Active Nonsegmental Vitiligo
DrugRitlecitinib
Pfizer
Phase 3
1,571
Mexico City, Morelia, Monterrey, Chihuahua City, Veracruz
2023-11-08
Active, closed
Determine Effectiveness of Anifrolumab In SYstemic Sclerosis (DAISY)
NCT05925803Systemic Sclerosis, Scleroderma
AstraZeneca
Phase 3
314
Chihuahua City, Guadalajara, Mexico City, San Luis Potosí City
2023-11-08
Recruiting
Multidimensional Intervention in Mexican Schoolchildren
NCT07185789Childhood Obesity, Pediatric Obesity, Childhood Overweight
Mexican National Institute of Public Health
Not applicable
200
Cuernavaca
2023-11-07
Active, closed
Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria)
NCT06087835Chronic Kidney Disease With High Proteinuria
DrugDapagliflozin
AstraZeneca
Phase 3
1,835
Mazatlán
2023-11-07
Active, closed
Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.
NCT05782907Ulcerative Colitis
DrugUpadacitinib
AbbVie
Phase 3
122
San Pedro Garza García
2023-11-06
Recruiting
Intraoperative Aberrometry vs Conventional Intraocular Lens Calculation, a Prospective Study.
NCT06219252Intraocular Lens Implantation, Cataract, Humans, Ocular, Refraction
Instituto de Oftalmología Fundación Conde de Valenciana
Not applicable
300
Mexico City
2023-11-03
Active, closed
A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT06054555Melanoma
DrugNivolumab
Amgen
Phase 3
633
León, Guadalajra, Mexico City, Monterrey, San Pedro Garza García, Juchitán de Zaragoza, San Luis Potosí City, Culiacán
2023-11-02
Recruiting
Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
DrugTreprostinil
United Therapeutics
Phase 3
698
2023-10-30
Recruiting
Diagnostic Performance of Controlling Nutritional Status as a Nutritional Screening Tool in Patients With Inflammatory Bowel Disease
NCT06648551Inflammatory Bowel Disease 5
Hospital General de Mexico
Observational
60
Mexico City
2023-10-28
Active, closed
A Randomized, Double-blind 2-arm, Followed by an Open-label 1-arm, NEPTUNUS Extension Study to Assess the Long-term Safety and Efficacy of Ianalumab in Patients With Sjogrens Syndrome.
NCT05985915Sjogrens Syndrome
DrugIanalumab
Novartis Pharmaceuticals
Phase 3
612
Guadalajara, Mexico City, Culiacán, Mérida, México
2023-10-27
Recruiting
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients
NCT05899608Non-Small Cell Lung Cancer
DrugsIvonescimab·Pembrolizumab
Summit Therapeutics
Phase 3
1,600
Guadalajara, La Paz, Mexico City, Monterrey
2023-10-26
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis
NCT06025578Progressive Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,057
Aguascalientes, México, Guadalajara, Morelia, Oaxaca City, Córdoba, Mérida, Chihuahua City
2023-10-25
Active, closed
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
NCT06052059Ulcerative Colitis
DrugTulisokibart
Merck Sharp & Dohme LLC
Phase 3
1,020
León, Guadalajara, Tlajumulco de Zuniga, Mexico City, Monterrey, Mérida, Chihuahua City, Oaxaca City
2023-10-25
Active, closed
ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions
NCT05949684Myelodysplastic Syndromes
DrugsEpoetin Alfa·Luspatercept
Bristol-Myers Squibb
Phase 3
402
Oaxaca City, Huixquilucan, Mexico City, Puebla City
2023-10-24
Recruiting
Eye Recovery Automation for Post Injury Dysfunction (iRAPID)
NCT06105892Convergence Insufficiency, Traumatic Brain Injury, Concussion, Mild
New Jersey Institute of Technology
Not applicable
100
2023-10-23
Active, closed
Physical Activity Intervention for the Improvement of Pain in Young, Hispanic Breast Cancer Survivors
NCT06260332Breast Cancer
New Mexico Cancer Research Alliance
Not applicable
25
2023-10-20
Active, closed
Nerve Protection Evaluation: Revision Cubital Tunnel Syndrome Decompression
NCT06117501Recurrent Cubital Tunnel Syndrome, Recalcitrant Cubital Tunnel Syndrome
Axogen Corporation
Not applicable
20
2023-10-19
Recruiting
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926Breast Cancer
DrugOvarian Function Suppression
NRG Oncology
Phase 3
3,960
Mexico City
2023-10-18
Recruiting
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
NCT05561387Plasma Cell Myeloma
DrugsDaratumumab and Hyaluronidase-fihj·Bortezomib·Lenalidomide·Dexamethasone
SWOG Cancer Research Network
Phase 3
510
2023-10-12
Recruiting
Cognitive Strategies for Optimizing Brain Health And Managing Transgenerational Vascular Risk Factors Post-Stroke
NCT06479174Stroke, Ischemic
University of New Mexico
Not applicable
40
2023-10-12
Active, closed
Enlicitide Decanoate (MK-0616 Oral PCSK9 Inhibitor) Cardiovascular Outcomes Study (MK-0616-015) CORALreef Outcomes
NCT06008756Arteriosclerosis, Hypercholesterolaemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
14,550
Tijuana, León, Pachuca, Guadalajara, Zapopan, Gustavo Adolfo Madero, Mexico City, General Escobedo
2023-10-09
Recruiting
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, ERASur Trial
NCT05673148Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal Cancer AJCC v8, Oligometastatic Colorectal Carcinoma
Alliance for Clinical Trials in Oncology
Phase 2
146
2023-10-09
Active, closed
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT05952557Breast Cancer, Early Breast Cancer
DrugsCamizestrant·Tamoxifen·Exemestane·Anastrozole
AstraZeneca
Phase 3
5,511
Alc. Cuauhtémoc, Mérida, San Luis Potosí City, Tuxtla Gutiérrez, Veracruz
2023-10-05
By invitation
A Long-Term Extension Study to Learn More About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus
NCT06044337Subacute Cutaneous Lupus Erythematosus, Chronic Cutaneous Lupus Erythematosus
DrugLitifilimab
Biogen
Phase 3
306
Mexico City, Chihuahua City, Guadalajara
2023-10-03
Recruiting
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
NCT05755386IC-MPGN
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
106
2023-10-02
Recruiting
Study of Oral Upadacitinib and Subcutaneous/Intravenous Tocilizumab to Evaluate Change in Disease Activity, Adverse Events and How Drug Moves Through the Body of Pediatric and Adolescent Participants With Active Systemic Juvenile Idiopathic Arthritis.
NCT05609630Juvenile Idiopathic Arthritis
DrugsUpadacitinib·Tocilizumab
AbbVie
Phase 3
90
Guadalajara
2023-10-02
Active, closed
Hyponatremia Volume Status Analysis by Point-of-care Ultrasound
NCT06013800Hyponatremia, Water-Electrolyte Imbalance
Universidad Veracruzana
Observational
80
Veracruz
2023-10-01
Recruiting
Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
NCT06079671Locally Advanced Cervical Cancer
DrugVolrustomig
AstraZeneca
Phase 3
800
Coyoacán, Culiacán, Guadalajara, Guadalajra, Mexico City, México, Monterrey
2023-09-22
Active, closed
A Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity
NCT06037252Type 2 Diabetes, Obesity
DrugTirzepatide
Eli Lilly and Company
Phase 2
414
Tijuana, Guadalajara, Cuauhtémoc, Ciudad de México, Mexico City, Monterrey, Ciudad Madero
2023-09-21
Active, closed
An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma
NCT06047080Large B-Cell Lymphoma
DrugsPolatuzumab Vedotin·Glofitamab·Doxorubicin·Prednisone
Hoffmann-La Roche
Phase 3
1,130
Mexico City, Mexico
2023-09-18
Recruiting
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
DrugsTaxotere·Doxorubicin·Docetaxel·Cyclophosphamide
SWOG Cancer Research Network
Phase 3
2,400
Mexico City
2023-09-15
Recruiting
Amplitude Titration to Improve ECT Clinical Outcomes
NCT05699226Depression, ECT, Cognitive Change
University of New Mexico
Not applicable
50
2023-09-14
Active, closed
A Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Participants With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) (IMbrave152)
NCT05904886Hepatocellular Carcinoma
DrugsTiragolumab·Avastin·Tecentriq·Atezolizumab
Hoffmann-La Roche
Phase 3
687
Mexico City, Oaxaca City
2023-09-14
Active, closed
A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis
NCT06003426Idiopathic Pulmonary Fibrosis
DrugAdmilparant
Bristol-Myers Squibb
Phase 3
1,255
Metepec, Morelia, Oaxaca City
2023-09-14
Recruiting
A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
NCT05878717Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic
DrugBelimumab
GlaxoSmithKline
Phase 2/3
300
Chihuahua City, Guadalajara, Mexico City, Mérida, Torreón
2023-09-13
Active, closed
TeleHealth Resources for IndiVidualizEd Goals (THRIVE) in Alcohol Recovery Study
NCT06074341Alcohol Use Disorder, Alcohol Drinking, Alcohol-Related Disorders
University of New Mexico
Not applicable
470
2023-09-13
By invitation
A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy
NCT05979441Myositis, Active Idiopathic Inflammatory Myopathy, Dermatomyositis, Polymyositis
DrugEfgartigimod PH20
argenx
Phase 3
240
Mexico City
2023-09-12
Active, closed
A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome
NCT05946941Sjögren's Syndrome
DrugDeucravacitinib
Bristol-Myers Squibb
Phase 3
774
León, Guadalajara, Mexico City
2023-09-11
Active, closed
Clairleafᵀᴹ: A Study to Test Long-term Treatment With BI 1291583 in People With Bronchiectasis Who Took Part in a Previous Study With This Medicine
NCT05846230Bronchiectasis
DrugVerducatib
Boehringer Ingelheim
Phase 2
268
Chihuahua City, Monterrey, Monterrey, Nuevo León, Oaxaca City, Tlalnepantla
2023-09-08
Recruiting
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
NCT05894239Metastatic Breast Cancer
DrugsPhesgo·Inavolisib
Hoffmann-La Roche
Phase 3
230
Guadalajara, Mexico City, Monterrey
2023-09-08
Recruiting
Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
NCT06051617Primary Biliary Cholangitis
DrugSeladelpar
Gilead Sciences
Phase 3
402
Cuernavaca, Irapuato, Mexico City, México, Oaxaca City, Veracruz
2023-09-07
Active, closed
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
NCT06033833Asthma
DrugAmlitelimab
Sanofi
Phase 2
335
Guadalajara, Mérida, Chihuahua City
2023-09-05
Recruiting
Ketogenic Diet and Diabetes Demonstration Project
NCT06115265Type 2 Diabetes, PreDiabetes, Obesity, Ketogenic Dieting
University of New Mexico
Not applicable
40
2023-09-05
Recruiting
Clinical Determinants and Adverse Reactions to Tropicamide/Phenylephrine in Hospitalized Patients.
NCT07178600Adverse Drug Effect, Phenylephrine, Hypertension, Cardiovascular Complication
Instituto de Oftalmología Fundación Conde de Valenciana
Observational
1,000
Mexico City
2023-09-02
Recruiting
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842Primary Biliary Cholangitis (PBC)
DrugElafibranor
Ipsen
Phase 3
276
Guadalajara, Jalisco, Mexico City, Monterrey, Yucatán
2023-08-31
Active, closed
A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC
NCT05884398Metastatic Castrate-sensitive Prostate Cancer
DrugApalutamide
Janssen Research & Development, LLC
Phase 3
420
Chihuahua City, Durango, Mérida, Querétaro
2023-08-31
Active, closed
A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations
NCT06052267Asthma
Teva Branded Pharmaceutical Products R&D LLC
Phase 3
2,772
Chihuahua City, Guadalajara, Monterrey, Oaxaca City, Villahermosa
2023-08-30
Recruiting
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
NCT06126224Psychosis Associated With Alzheimer's Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
500
Saltillo Centro, Zona Urbana Río Tijuana, Zapopan, Monterrey, Culiacán, México
2023-08-28
Active, closed
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
NCT05602194B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Lymphoblastic Lymphoma
DrugsOncaspar·Calaspargase Pegol·PEG asparaginase·Pegaspargase
Children's Oncology Group
Phase 3
440
2023-08-24
Recruiting
A Study to Investigate the Efficacy and Safety of Tezepelumab Compared With Placebo in Children 5 to < 12 Years Old With Severe Asthma
NCT06023589Asthma
DrugTezepelumab
AstraZeneca
Phase 3
231
Chihuahua City, Guadalajara, Mexico City, Veracruz
2023-08-24
Active, closed
Effect of a Food Supplement with Natural Extracts of Cocoa, Amaranth Seed and Ginger in Overweight or Obese Patients
NCT06769035Oxidative Stress, Inflammation Biomarkers, Obesity and Overweight
University of Guadalajara
Not applicable
40
Guadalajara
2023-08-20
Active, closed
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
NCT05797610Primary IgA Nephropathy
Hoffmann-La Roche
Phase 3
459
Fracc Lomas Del Campestre, Morelia, Cuernavaca
2023-08-08
Active, closed
A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer
NCT05800015Non-small Cell Lung Cancer
DrugsFianlimab·Paraplatin·Cemiplimab·Pemetrexed
Regeneron Pharmaceuticals
Phase 2/3
160
2023-08-08
Recruiting
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
NCT05947851Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Chronic Lymphocytic, Small-Cell Lymphoma, Lymphoma, Small Lymphocytic
DrugsNemtabrutinib·Venetoclax·Rituximab
Merck Sharp & Dohme LLC
Phase 3
735
Mexico City, Morelia
2023-08-08
Active, closed
Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries
NCT06002126Cervix Cancer, HPV Infection, Cervical High Grade Squamous Intraepithelial Lesion, HIV Infections
Weill Medical College of Cornell University
Not applicable
1,001
Cuernavaca
2023-08-02
Recruiting
Caspofungin for Pneumocystis Pneumonia in PLWHIV.
NCT06691321HIV-1-infection, Pneumocystis Pneumonia
Instituto Nacional de Enfermedades Respiratorias
Observational
60
Mexico City
2023-08-01
Rows per page Showing 701–800 of 1579
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Mexican investigative site. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-mexico?page=8

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Mexico and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 1,579 studies in total at the last sync on 26 Sep 2026, 19:45 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

How many clinical trials are recruiting in Mexico?

711 of the 1,579 studies in this register are recruiting new participants as of the 26 Sep 2026, 19:45 UTC sync. A further 64 have not yet opened recruitment, 742 are active but closed to new participants, and 62 are enrolling by invitation only. Eligibility for any study is decided by its study team.

This register, in your inbox every Friday

One email a week with how many trials are recruiting in Ireland, new EMA and FDA approvals and medicine shortages, built from the same public registers as this page.

Free. Unsubscribe from any email with one click. See our privacy policy.

→

Browse trials by condition

Breast Cancer (37) Obesity (27) Systemic Lupus Erythematosus (21) Non-Small Cell Lung Cancer (15) Prostate Cancer (15) Carcinoma, Non-Small-Cell Lung (15) Non-small Cell Lung Cancer (14) Asthma (14) Overweight (12) Acute Myeloid Leukemia (12) Multiple Myeloma (12) Ovarian Cancer (11) Malignant Solid Neoplasm (10) Type 2 Diabetes (10) Chronic Kidney Disease (10)
→

Browse trials by site location

Mexico City (586) Monterrey (370) Guadalajara (342) Chihuahua City (175) Mérida (135) Oaxaca City (122) México (99) Veracruz (92) Culiacán (85) León (85) Aguascalientes (84) Cuernavaca (70) San Luis Potosí City (69) Zapopan (51) Puebla City (50)
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.